Aileron Therapeutics at ASCO 2017 Annual Meeting

Saturday, June 3, 2017 3:39 p.m. ET  
Title
Aileron Therapeutics at ASCO 2017 Annual Meeting
Date / Time
06/03/17 3:39 p.m. ET
Description

Oral Abstract Session: “Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas”
Session Title: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Abstract #:2505

VIEW ABSTRACT
VIEW PRESENTATION